Intervention not reported
Improvement of clinical status: all initial symptoms resolved (asymptomatic) at day 14 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in improvement of clinical status: all initial symptoms resolved… (low certainty).
1 finding from 1 review
Intervention not reported
Improvement of clinical status: time to symptom resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
QoL (physical component) at up to 28 days, measured on the PROMIS Global‐10 scale and normalized to values from 16.2, low QoL, to 67.2, maximum QoL · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in qoL (physical component) at up to 28 days, measured on the PROMIS… (high certainty).
1 finding from 1 review
Intervention not reported
QoL (mental component) at up to 28 days, measured on the PROMIS Global‐10 scale and normalized to values from 21.2, low QoL, to 67.6, maximum QoL · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in qoL (mental component) at up to 28 days, measured on the PROMIS… (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events during the trial period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in serious adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events during the trial period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in any adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at day 7 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in viral clearance at day 7 (low certainty).
1 finding from 1 review
Intervention not reported
Worsening of clinical status: participants with new need for invasive mechanical ventilation or death at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes worsening of clinical status: participants with new need for… (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement of clinical status: participants discharged alive at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in improvement of clinical status: participants discharged alive at day… (low certainty).
1 finding from 1 review
Intervention not reported
QoL at longest · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes serious adverse events during the trial period (very low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in any adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at day 7 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in viral clearance at day 7 (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in all‐cause mortality at day 28 (moderate certainty).
1 finding from 1 review
Intervention not reported
Worsening of clinical status: admission to hospital or death within 28 days · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in worsening of clinical status: admission to hospital or death within… (low certainty).
1 finding from 1 review
Seizure recurrence at 5 years after randomisation · people with neurocysticercosis
Albendazole showed no clear difference in seizure recurrence ‐ all participants compared with placebo or no anthelmintics (low certainty).
1 finding from 1 review
Seizure recurrence ‐ participants with a single cyst · people with neurocysticercosis
Albendazole probably leads to lower seizure recurrence ‐ participants with a single cyst compared with placebo or no anthelmintics (moderate certainty).
1 finding from 1 review
Seizure recurrence ‐ participants with multiple (> 1) cysts · people with neurocysticercosis
It is very uncertain whether albendazole changes seizure recurrence ‐ participants with multiple (> 1) cysts compared with placebo or no anthelmintics (very low certainty).
1 finding from 1 review
Complete radiological clearance of lesions · people with neurocysticercosis
Albendazole probably leads to higher complete radiological clearance of lesions compared with placebo or no anthelmintics (moderate certainty).
1 finding from 1 review
Evolution of cysts · people with neurocysticercosis
Albendazole probably leads to higher evolution of cysts compared with placebo or no anthelmintics (moderate certainty).
1 finding from 1 review